A Study of Treatment Delivery Preference In People With Kidney Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent otrzymuje standardowe leczenie raka nerki (nivolumab lub pembrolizumab)
- •Pacjent ma co najmniej 6 dawek leczenia pozostałych do podania
- •Wiek co najmniej 18 lat
- •Umiejętność czytania i mówienia po angielsku
- •Umożliwienie wyrażenia zgody na uczestnictwo w badaniu
✗ Disqualifies
- •Pacjent uczestniczy jednocześnie w innym badaniu klinicznym z nowymi lekami
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, United States
Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)
Commack, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, United States
Trial contact
Sahil Doshi, MD
Thomas Atkinson, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.